A securities class action has been filed against Mereo BioPharma Group plc on behalf of investors who bought or acquired the company’s ADSs between June 5, 2023 and December 26, 2025. The suit alleges the company misled investors about the likelihood that its Phase 3 ORBIT and COSMIC studies of setrusumab in osteogenesis imperfecta would meet the primary endpoint of reducing annualized fracture rates; the company later reported the trials did not meet that endpoint, and the ADS price fell sharply. Investors seeking to be appointed lead plaintiff must file by April 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041340PRIMZONEFULLFEED9665891) on March 04, 2026, and is solely responsible for the information contained therein.